Evidence mapPaperPMID 9562349Full record

ArticleDiabetologia1998

Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I]metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients.

D Ziegler, F Weise, K J Langen, R Piolot, C Boy, A Hübinger, H W Müller-Gärtner, F A Gries

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03912909 (Effects of SGLT-2 Inhibition on Sympathetic Nervous System Activity in Humans), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03912909 phase4unknown statusstarted 2018, after this paper: background citation

Effects of SGLT-2 Inhibition on Sympathetic Nervous System Activity in Humans

Ran2018Enrolled30Registered outcomes7Posted comparisons0ConditionsMetabolic Syndrome, Obesity, Type 2 Diabetes MellitusArmsEmpagliflozin Oral Tablet [Jardiance], Placebo Oral Tablet
Open the trial in the graph
3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Long-term effect of acetyl-L-carnitine on myocardial 123I-MIBG uptake in patients with diabetes.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2000
    Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Autonomic imbalance: prophet of doom or scope for hope?Diabetic medicine : a journal of the British Diabetic Association · 2011
    Review
  11. Article
  12. Article
  13. Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients.European journal of nuclear medicine and molecular imaging · 2008
    Article
  14. Article
  15. Article
  16. Article
  17. MIBG imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

D ZieglerDiabetes Research Institute at the Heinrich Heine University, Düsseldorf, Germany.
F Weise
K J Langen
R Piolot
C Boy
A Hübinger
H W Müller-Gärtner
F A Gries

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic cardiovascular autonomic neuropathy (CAN) has been directly characterized by reduced or absent myocardial [123I]metaiodobenzylguanidine (MIBG) uptake, but there is no information available on the relationship between the myocardial adrenergic innervation defects and long-term glycaemic control. In a prospective study over a mean of 4 years we examined myocardial sympathetic innervation in 12 Type 1 (insulin-dependent) diabetic patients using MIBG scintigraphy (absolute and relative global MIBG uptake at 2 h p.i.) in conjunction with cardiovascular autonomic function tests, QTc interval, and QT dispersion. Six healthy non-diabetic subjects served as controls for the MIBG scintigraphy at baseline. HbA1c was measured twice a year. One patient, in whom MIBG accumulation was reduced maximally, died during follow up. Among the remaining patients 5 had good or borderline glycaemic control (mean HbA1c < 7.6%; Group 1), whereas 6 patients were poorly controlled (mean HbA1c > or = 7.6%; Group 2). Absolute global MIBG uptake increased from baseline to follow-up by 260 (-190-540) [median (range)] cpm/g in Group 1 and decreased by -150 (-450-224) cpm/g in Group 2 (p < 0.05 vs Group 1). Relative global MIBG uptake decreased by -1.7 (-3.4-9.4) % in Group 1 and by -4.7 (-17.4-1.3) % in Group 2 (p < 0.05 vs Group 1). No differences between the groups were noted for the changes in the automatic function tests, QTc interval, and QT dispersion. In conclusion, long-term poor glycaemic control constitutes an essential determinant in the progression of left ventricular adrenergic dysinnervation which may be prevented by near-normoglycaemia. Evaluation of susceptibility to metabolic intervention may be superior when CAN is characterized directly by MIBG scintigraphy rather than by indirect autonomic function testing.

Indexed as

3-IodobenzylguanidineRadiopharmaceuticalsAdultAgedBiomarkersBlood GlucoseBlood PressureDiabetes Mellitus, Type 1Diabetic NeuropathiesDiabetic RetinopathyElectrocardiographyFemaleGlycated HemoglobinHeartHeart RateHumans3-IodobenzylguanidineBiomarkersBlood GlucoseGlycated HemoglobinRadiopharmaceuticals

Identifiers

PMID9562349

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.